Abstract 198P
Background
Geographic access to medical care varies for nearly every specialty in India. Brachytherapy (BT) is emblematic of several of these access difficulties since it necessitates specialized equipment, the capacity to maintain a radioactive source, and particular skill sets. To quantify the unmet infrastructure needs, we conducted this study to report the availability of brachytherapy treatment units in relation to state-level population, and gynaecologic cancer incidence in India.
Methods
The availability of BT resources at the state level in India was obtained from the IAEA database. The population of each state was estimated using data from the Government of India's census. Using National Cancer Registry program data, the number of cancer cases was approximated for each state and union territory. The total number of gynaecological cancers that required BT was determined. BT capacity was estimated at three procedures per unit per day for 240 days(Excluding holidays and weekends) as follows: number of BT units x 240 x 3. The disparity between available and needed infrastructure was used to compute the deficit in BT units. Number of BT facilities available in medical colleges across India were calculated. The BT infrastructure was also compared to those of other nations in terms of the number of BT units available per million people and for various malignancies.
Results
India has 1 brachytherapy unit every 42,93,031 population. With respect to state wise data, 21 states and union territories had deficits of brachytherapy units. The maximum deficit was seen in Uttar Pradesh. The maximum units per 10,000 cancer patients was noted in Delhi (7) and the least was noted in the North Eastern states (<1). In brachytherapy of gynaecological cancers a deficit ranging from 1-75 units were noted across the states. It was noted that only 104 out of the 613 medical colleges in India had BT facilities. India had 1 BT machine for every 4181 cancer patients when compared to USA ( 2956 patients), Germany (2754 patients) and Japan (4303 patients).
Conclusions
The study identified the deficits of BT facilities in India and provides a direction for the development of BT infrastructure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abhishek Krishna.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
186P - Degradation of BRCA2 expression by hyperthermia sensitizes HRD-negative (BRCA2 wild-type) ovarian cancer cells to niraparib
Presenter: Junyang Li
Session: Poster viewing 03
187P - BUB1 (2530C>T) polymorphism and expression affects chemotherapy response and predicts poor prognosis in advanced epithelial ovarian cancer
Presenter: Sinjini Sarkar
Session: Poster viewing 03
188P - Spatial transcriptomic analysis of tumor tissue in ovarian cancer patients treated with neoadjuvant chemotherapy
Presenter: Irina Larionova
Session: Poster viewing 03
189P - LncRNA NKILA as a negative regulator of NFkB in ascites in ovarian cancer
Presenter: Dinara Dolgova
Session: Poster viewing 03
190P - Real-world applications of poly (ADP-ribose) polymerase inhibitors for ovarian cancer: A single-center study in China
Presenter: dengfeng wang
Session: Poster viewing 03
191P - Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
Presenter: N Thejeswar
Session: Poster viewing 03
192P - Human epididymis protein 4 as a predictor of response to neoadjuvant chemotherapy in epithelial ovarian cancer
Presenter: Sarada Planjery
Session: Poster viewing 03
193P - Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice: Experience of re-challenge mode of olaparib usage
Presenter: Alexander Sultanbaev
Session: Poster viewing 03
194P - A study of the treatment response of concomitant external beam radiotherapy (EBRT) and intracavitary brachytherapy in the management of locally advanced carcinoma of uterine cervix
Presenter: Asish Chowdhury
Session: Poster viewing 03
195P - Awareness of human papillomavirus (HPV) infection, cervical cancer (CC), and vaccine among females in Sultanate of Oman
Presenter: Abdulrahman Al-Mirza
Session: Poster viewing 03